RNAZ
Transcode Therapeutics, Inc.
$8.44
+0.67 (+8.62%)
At close · Jul 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern within one year of the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed May 15, 2026
Market Cap
$8.02M
Shares
950,302
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.44
Open$7.59
Day$7.59–8.50
52W$3.82–20.99
Avg vol 30d109K
Short int57K · 5.9% float · 1.0d
Short vol26%
Last earningsApr 5, 2024
DataJul 2021–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−5% below
+
Price vs 50-day avg
+33% above
◦
RSI (14)
68 · neutral
+
MACD trend
positive
◦
52-week position
27% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $6 › 200d $9 — 200d above 50d
+
Institutional flow
+33% holders QoQ · +4 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
5.95% of float · ▲ +100.9% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
8 holders — mid 1-yr range
Fundamentals
Strong
+
EPS growth
+96% Y/Y
−
Free cash flow
$-19.5M
+
Balance sheet
net cash $17.8M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−5% below
Bearish
Price vs 50-day avg
+33% above
Bullish
RSI (14)
68 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
27% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
+33% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.95% of float · ▲ +100.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $4
Now $8 · 27%
52-wk high $21
vs 200-day avg -5%
vs 50-day avg +33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNAZ
this stock
Transcode Therapeutics, Inc.
|
$8.02M | +23.6% | — | — | 5.9% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNAZ | +61.1% | +50.7% | +6.2% | +35.9% | +23.6% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +60.2% | +49.3% | -1.4% | +35.8% | +13.9% |